384 studies found for:    biogen | biogen
Show Display Options
RSS Create an RSS feed from your search for:
biogen | biogen
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Biogen Multiple Sclerosis Pregnancy Exposure Registry
Conditions: Multiple Sclerosis;   Exposure During Pregnancy
Interventions: Drug: dimethyl fumarate;   Drug: Peginterferon beta-1a;   Drug: Dalclizumab High Yield Process
2 Completed Open-Label Safety Extension Study of Avonex
Condition: Multiple Sclerosis
Intervention: Drug: Interferon beta-1a (Avonex)
3 Terminated 104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants
Condition: Rheumatoid Arthritis
Intervention: Biological: Baminercept alfa (BG9924)
4 Terminated BG9924 in Combination With Methotrexate Extension of Study 104RA203 (NCT 00458861)
Condition: Rheumatoid Arthritis
Intervention: Drug: BG9924
5 Completed A Healthy Volunteer Study to Establish the Bioequivalence of BG00012 Supplied by 2 Different Commercial Manufacturers
Condition: Healthy
Interventions: Drug: dimethyl fumarate - Reference form;   Drug: dimethyl fumarate - Test form
6 Recruiting An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice
Condition: Multiple Sclerosis
Intervention: Drug: Fampridine
7 Terminated Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Lumiliximab + FCR;   Drug: FCR
8 Completed Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants
Condition: Rheumatoid Arthritis
Interventions: Biological: Baminercept alfa 1;   Biological: Placebo;   Biological: Baminercept alfa 2;   Biological: Baminercept alfa 3;   Biological: Baminercept alfa 4;   Biological: Baminercept alfa 5
9 Completed ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.
Condition: Multiple Sclerosis
Intervention:
10 Completed A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)
Condition: Relapsing Forms of Multiple Sclerosis
Interventions: Procedure: Plasma exchange;   Drug: natalizumab treatment
11 Completed A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Participants With Multiple Sclerosis
Condition: Exercise
Intervention:
12 Completed
Has Results
A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients
Condition: Relapsing Remitting Multiple Sclerosis (RRMS)
Intervention: Drug: BG00002 (natalizumab)
13 Completed Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy
Condition: Multiple Sclerosis
Intervention: Drug: low immunogenic interferon-beta-1a
14 Completed Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: Interferon-beta-1a;   Drug: methylprednisolone
15 Recruiting A Study of Multiple Doses of ISIS SMNRx (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
Condition: Spinal Muscular Atrophy
Intervention: Drug: ISIS SMNRx (ISIS 396443)
16 Not yet recruiting Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes
Conditions: Multiple Sclerosis;   Acute Optic Neuritis
Intervention: Drug: BIIB033 (opicinumab)
17 Not yet recruiting PK and Safety Study of BIIB074 in Healthy Japanese and Caucasian Participants
Condition: Trigeminal Neuralgia
Interventions: Drug: BIIB074;   Drug: Placebo
18 Recruiting A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Study of BIIB068 in Healthy Participants
Condition: Systemic Lupos Erythematosus, SLE
Interventions: Drug: BIIB068;   Drug: Placebo
19 Recruiting Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants
Condition: Alzheimer's Disease
Intervention: Drug: aducanumab
20 Not yet recruiting Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
Condition: Multiple Sclerosis
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years